Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase III trial to evaluate the role of checkpoint inhibition in women with ovarian cancer. This...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | anglais |
| Publié: |
2018
|
| Accès en ligne: | https://doi.org/10.2217/fon-2018-0070 https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0070 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|